As a secondary objective of this trial, IL-13Rα2-CAR-T cell persistence in cerebrospinal fluid (CSF), tumor cavity fluid (TCF) and blood was monitored throughout treatment (Extended Data Fig. 4). The gene discussed is IL13RA2; the disease is neoplasm.